Summary of Ascendis Pharma Conference Call Company Overview - **Company**: Ascendis Pharma (NasdaqGS:ASND) - **Product**: YUVIWEL, a treatment for achondroplasia - **FDA Approval**: YUVIWEL is the third FDA-approved drug from Ascendis Pharma, with plans for commercial launch in the U.S. in Q2 2026 [5][34] Key Points and Arguments FDA Approval and Product Details - YUVIWEL is the first and only once-weekly treatment for children with achondroplasia, utilizing TransCon technology to extend the half-life of C-type natriuretic peptide (CNP) from minutes to 5-6 days [6][7] - The FDA approval was based on data from three randomized double-blind placebo-controlled trials, including the pivotal ApproaCH Trial [7][8] - A Rare Pediatric Disease Priority Review Voucher was granted alongside the approval, allowing for priority review of a future drug application [8] Clinical Efficacy - In the pivotal ApproaCH Trial, children treated with YUVIWEL achieved an annualized growth velocity (AGV) of 5.9 cm/year compared to 4.4 cm/year for placebo, with a statistically significant treatment difference of 1.5 cm/year [20] - The treatment demonstrated improvements in height Z-scores across all predefined subgroups, including age, sex, and geographic region [21] Market Opportunity - The U.S. pediatric achondroplasia prevalence is estimated at around 2,600, with approximately 30% currently on pharmacological treatment [26] - There is a significant unmet need in the market, with many patients either not on treatment or having discontinued previous therapies due to tolerability or perceived lack of benefit [27] Commercial Strategy - Ascendis Pharma plans to engage with centers of excellence, thought leaders, and patient advocacy groups to educate stakeholders on YUVIWEL's clinical value proposition [28] - The company aims to optimize the patient experience and ensure affordability through programs that may allow eligible patients to pay as little as $0 a month [30] - Initial uptake is expected to come from both switches from existing therapies and treatment-naive patients [47] Future Plans - Ascendis Pharma has a roadmap to achieve $5 billion in product revenue by 2030, focusing on expanding the label for existing products and developing new therapies [14] - Plans include exploring indications for hypochondroplasia and adult patients with achondroplasia [70] Safety and Administration - YUVIWEL is designed to minimize injection site reactions and does not require food intake before administration, which is seen as a meaningful differentiation from existing therapies [22][55] - The product can be stored at room temperature for up to 6 months, enhancing convenience for patients [24] Additional Important Information - The company has a strong existing infrastructure from previous product launches, which will be leveraged for YUVIWEL [59] - Pricing for YUVIWEL has not yet been disclosed, but a premium pricing strategy is anticipated due to the product's differentiated benefits [45][46] - The company is prepared for potential reimbursement challenges and is engaging with payers to facilitate access [76] This summary encapsulates the critical aspects of the conference call, highlighting the company's strategic direction, product details, market potential, and future plans.

Core Viewpoint - Viesheng Pharmaceutical-B (02561) has seen a stock increase of over 7% following the approval of its core product, lonapegsomatropin, by the National Medical Products Administration of China for treating growth hormone deficiency in children aged 3 and above [1] Group 1: Product Approval - Lonapegsomatropin, marketed as维臻高, has received official approval for use in treating growth hormone deficiency in children and adolescents [1] - The product is developed using Ascendis Pharma's innovative TransCon technology and is the first growth hormone regimen approved for children in the United States [1] Group 2: Commercialization Plans - Following the BLA approval, the company has initiated a comprehensive commercialization plan to ensure supply and expand market coverage [1] - A commercialization supply agreement has been established with Ascendis Pharma to secure the product's market launch [1] - The company is enhancing its commercialization capabilities by building a dedicated team and implementing tailored strategies for commercialization, physician awareness, and market access [1]

Core Viewpoint - Viesheng Pharmaceutical-B (2561.HK) has seen a significant stock price increase, reaching a new high since December 19 of the previous year, driven by the anticipated approval of its core product, Lonapegsomatropin, which is expected to reshape the growth hormone market [1][2] Group 1: Stock Performance - Viesheng Pharmaceutical-B opened high and surged by 9.9% to HKD 38.2, marking a year-to-date increase of over 16%, outperforming the Hang Seng Index, which rose over 4% during the same period [1] Group 2: Product Development - The Insight database indicates that Lonapegsomatropin is set to exit the supplementary data task on January 12, 2026, and is expected to receive approval soon [1] - Lonapegsomatropin, a long-acting growth hormone prodrug introduced from Ascendis Pharma, is the first long-acting weekly formulation approved for pediatric growth hormone deficiency (GHD) in the U.S. and Europe [1] - The domestic growth hormone market primarily consists of daily formulations, and the introduction of a weekly formulation is anticipated to significantly enhance patient compliance and address unmet clinical needs [1] Group 3: Competitive Advantage - According to Guohai Securities, Lonapegsomatropin, based on TransCon technology, is expected to be launched soon and demonstrates superior efficacy and equivalent safety compared to short-acting growth hormones [2] - Lonapegsomatropin is the only long-acting growth hormone that continuously releases unmodified human growth hormone in the body between weekly doses, validated by completed Phase III trials in China [2] - It has shown superior efficacy and equivalent safety in positive drug control and parallel group trials compared to short-acting growth hormones [2]

Core Viewpoint - Guohai Securities reports that the long-acting growth hormone, Lonpei, based on TransCon technology, is expected to be launched soon, demonstrating superior efficacy and equivalent safety compared to short-acting growth hormones [1] Company Summary - Lonpei growth hormone was introduced by Weisheng Pharmaceutical in November 2018 through a licensing agreement with Ascendis Pharma [1] - The growth hormone utilizes TransCon (transient conjugation technology) for long-acting delivery, making it the only long-acting growth hormone that continuously releases unmodified human growth hormone between weekly doses [1] - Completed Phase III pivotal trials in China have validated that Lonpei is the only long-acting growth hormone showing superior efficacy and equivalent safety in comparison to short-acting growth hormones in positive drug control and parallel group trials [1] - Weisheng Pharmaceutical anticipates that Lonpei will receive domestic approval for marketing in the fourth quarter of 2025, suggesting that investors should closely monitor the company in the near term [1]

Financial Data and Key Metrics Changes - Total product revenue for Q2 2025 was €153,700,000, with a negative foreign currency exchange impact of €7,600,000 [27] - Skytrofa revenue for the quarter was €50,700,000, including a €1,800,000 negative currency impact [27] - Eurvipath revenue more than doubled to €103,000,000, up from €44,700,000 in Q1 2025, despite a negative currency headwind of €5,800,000 [27] - R&D costs decreased to €72,000,000 from €83,500,000 year-over-year, while SG&A expenses increased to €107,600,000 from €74,300,000 [29] - The company ended Q2 2025 with cash and cash equivalents totaling €494,000,000, down from €518,000,000 as of March 31 [30] Business Line Data and Key Metrics Changes - Revenues for Europad in Q2 reached €103,000,000, more than double that of Q1 [10] - Skytrofa revenues were €51,000,000, with growth driven by new patient starts and recent label expansion for adult growth hormone deficiency [24] - The company expects continued revenue growth driven by the strength of the global launch of Europad [30] Market Data and Key Metrics Changes - In the U.S., over 1,500 prescribers wrote prescriptions for around 3,100 unique patients for Europad, reflecting strong demand [11] - The company has recognized revenue from more than 30 countries and has commercial agreements covering over 75 countries [15] - The U.S. launch of Europad is progressing well, with expectations for additional commercial launches in Europe and Japan [16][32] Company Strategy and Development Direction - The company aims to achieve blockbuster status for multiple products and expand its innovation engine [8] - Focus on building long-term leadership in the treatment of hypoparathyroidism and growth disorders through differentiation, demand, and access [13] - The company is preparing for future growth opportunities and ongoing collaborations with Novo Nordisk for TransCon-based products in metabolic and cardiovascular diseases [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued strong demand for Europad and the potential for it to become a blockbuster product [10] - The company anticipates becoming cash flow positive on a quarterly basis this year [29] - Management highlighted the importance of payer approvals and the ongoing efforts to improve the patient experience and access to treatment [34] Other Important Information - TransCon Growth Hormone is now approved in the U.S. for adults with growth hormone deficiency, and the company plans further label expansions [5] - The FDA granted priority review for TransCon CNP, recognizing its potential to improve treatment for achondroplasia [9] - The company is advancing new clinical data and preparing for additional key label expansions [25] Q&A Session Summary Question: Continuation of enrollment trends - Management confirmed that the number of unique patients enrolled grew to 3,100 by the end of Q2, indicating steady state growth [36][38] Question: Improving conversion from enrollment to treatment - Management acknowledged ongoing efforts to improve the time from enrollment to treatment, with expectations for better results in the second half of the year [45][49] Question: Patient demographics and severity - Management clarified that there is no medical definition for severity in hyperparathyroidism, and they are focusing on addressing physicians who see a high number of patients [53][55] Question: Future revenue expectations - Management indicated that they expect continued strong revenue growth in the U.S. and Europe, with a focus on expanding commercial launches [61][62] Question: Compliance and patient retention - Management reported low discontinuation rates in Europe, indicating strong patient retention and satisfaction with the therapy [72][73] Question: Reporting enrollment forms - Management confirmed that they will continue to report necessary KPIs related to enrollment and treatment until a steady state is achieved [69][70] Question: Titration period and costs - Management noted that the titration period is successful, but they are still assessing real-world data on costs post-titration [98][101]